Strides Pharma Share Price

Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies. Strides Pharma share price on the NSE and BSE is a reflection of how market participants respond to a company’s performance and broader business developments within its industry. It captures the sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries.

Strides Pharma stock price is influenced by various factors such as earnings reports, new product approvals from the USFDA, the resolution of regulatory observations, currency fluctuations, and the overall demand for generic medicines. In the longer run, strategic initiatives like portfolio expansion, geographic diversification, and the growth of its branded generics business in emerging markets affect the stock market sentiments. All these factors must be closely monitored to have an idea about the Strides Pharma stock price movements.

Strides Pharma live share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant ͏monitoring of Strides Pharma live price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market.

Furthermore, monitoring the Strides Pharma share͏ price today helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identifypossible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook.

STRIDES PHARMA SCIENCE LIMITED COMPANY FUNDAMENTALS

a. Company Background

Strides Pharma Science Limited is an Indian pharmaceutical company incorporated on June 28, 1990, and registered with its corporate headquarters in Bengaluru, Karnataka, India. The company operates in the global pharmaceutical industry, focusing on the development, manufacturing, and commercialization of a wide range of generic and specialty medicines. Over the years, it has expanded its footprint to more than 100 countries, serving both regulated markets such as the United States and Europe, as well as emerging and institutional markets.

Strides Pharma’s operations are supported by a manufacturing network spread across India, Italy, Kenya, and the United States, with several facilities approved by regulatory authorities including the USFDA. The company emphasizes niche and complex pharmaceutical formulations, particularly in therapeutic segments such as anti-infectives, central nervous system, and oncology. It also operates a business-to-business platform, Synergice, to facilitate partnerships and global distribution.

In addition to manufacturing, the company invests in research and development to strengthen its product pipeline and regulatory capabilities. Its activities also include supplying medicines to institutional programs addressing diseases such as HIV/AIDS, malaria, and tuberculosis, particularly in Africa. The company’s growth reflects its transition from a domestic enterprise to a multinational pharmaceutical manufacturer with diversified market exposure.

b. Company Product Lines

• Generic pharmaceutical formulations across multiple therapeutic areas

• Anti-infective drugs targeting bacterial and viral infections

• Central Nervous System (CNS) medications

• Oncology (cancer care) formulations

• Cardiovascular and metabolic disorder drugs

• Gastrointestinal medications

• Over-the-counter (OTC) healthcare products

• Soft gelatin capsules and complex dosage forms

• Institutional medicines for HIV/AIDS, malaria, and tuberculosis programs

• Specialty and niche pharmaceutical products for regulated markets

• Sterile and non-sterile formulations

• Pediatric and oral dosage formulations

• Products developed through in-house R&D and licensed partnerships

• Contract manufacturing products via B2B platform (Synergice)

• Regulatory-compliant formulations for US, Europe, and emerging markets

c. Company Revenue Model

• Revenue primarily generated through sale of generic pharmaceutical products in regulated markets such as the US

• Significant earnings from emerging markets and branded generics, especially in Africa and Asia

• Institutional sales through partnerships with global health organizations and governments

• Contract manufacturing and B2B partnerships via the Synergice platform

• Licensing and supply agreements with international pharmaceutical companies

• Focus on high-margin niche and complex generics to improve profitability

• Revenue diversification across regulated (USFDA-approved) and semi-regulated markets

• Income from product filings and approvals, especially abbreviated new drug applications (ANDAs)

• Strategic partnerships contributing to co-development and distribution revenue streams

• Manufacturing services for third parties leveraging global production facilities

• Investment in R&D to support long-term pipeline-driven revenue growth

• Cost optimization through global manufacturing footprint and supply chain efficiencies

• Expansion into specialty segments to enhance value realization

d. Geographic Presence

• Strong presence in India, serving as headquarters and key manufacturing hub

• Significant footprint in the United States, one of its largest regulated markets

• Operations across Europe, including manufacturing in Italy

• Established presence in Africa, especially through Kenya-based manufacturing and institutional programs

• Coverage across Asia-Pacific (APAC) markets with distribution networks

• Participation in Institutional Access Markets, supplying medicines to global health programs

• Exports to over 100 countries worldwide

• Strategic focus on both regulated markets (US, EU) and emerging markets (Africa, Asia, Latin America)

• Regional business units aligned to Americas, EMEA (Europe, Middle East, Africa), and APAC

• Localized strategies such as “In Africa, For Africa” to address regional healthcare needs

• Global supply chain supported by multi-continent manufacturing facilities

• Partnerships with healthcare organizations, governments, and distributors worldwide

e. Leadership

Some of the key leaders of Strides Pharma Science Limited as of March 2026 are:

• Arun Kumar – Executive Chairman & Managing Director

• Badree Komandur – Managing Director & Group CEO

• Aditya Kumar – Executive Director (Business Development)

• Ramaraju Pvs – Chief Operating Officer

• Vikesh Kumar – Group Chief Financial Officer

• Umesh Kale – Chief Quality Officer

• Manjula Ramamurthy – Company Secretary & Compliance Officer

• Homi Rustam Khusrokhan – Non-Executive & Independent Director

• Kausalya Santhanam – Non-Executive & Independent Director

• Ameet Hariani – Non-Executive & Independent Director

• Subir Chakraborty – Non-Executive & Independent Director

• Mukta Malik Arora – Independent Director

f.  Key Milestones

• 1990: Company incorporated as Strides Pharma Science Limited

• 2000s: Expansion into international markets and regulated geographies

• 2010–2015: Strengthening of US generics business and regulatory approvals

• 2016: Strategic restructuring and focus on core pharmaceutical operations

• 2018: Expansion of global manufacturing footprint across multiple continents

• 2020: Increased focus on complex generics and specialty products

• 2021–2023: Growth in institutional and emerging market segments

• 2024 onwards: Continued expansion of B2B platform (Synergice) and global partnerships

g. Industry Perspective

Global Pharmaceutical and Generics Industry, in which Strides Pharma operates, is one of the largest and fastest-evolving segments of the global healthcare ecosystem. The global pharmaceutical market was valued at approximately USD 1.74 trillion in 2025 and is projected to reach around USD 2.77 trillion by 2033, growing at a CAGR of about 6.0–6.1% during the forecast period.

Within this, the generic pharmaceuticals segment—a core focus area for companies like Strides Pharma—was estimated at USD 454.7 billion in 2025 and is expected to reach USD 770 billion by 2033, expanding at a CAGR of 6.5%. Growth in generics is driven by patent expirations, cost-containment pressures, and increased access to affordable medicines. Additionally, the broader generics market is forecast to grow at around 7.2% CAGR through 2033, reflecting sustained global demand.

Emerging markets in Asia-Pacific and Africa are expected to witness higher growth rates (around 7–9%), supported by expanding healthcare access and government initiatives. Meanwhile, specialized segments such as biosimilars and complex generics are projected to grow even faster (above 8–9% CAGR), driven by technological advancements and regulatory approvals.

Overall, the industry outlook remains positive, supported by rising chronic disease prevalence, aging populations, and increasing demand for affordable, high-quality medicines globally.

Strides Pharma Stock Market Presence: Listings & Index Representation

Strides Pharma Science Limited is listed on the BSE (Bombay Stock Exchange) (BSE: 532531) and the NSE (National Stock Exchange) (NSE: STAR ) after its initial public offering in 2000.

Strides Pharma is a well-established entity in the Indian stock market, listed on major exchanges such as NSE (STAR) and BSE (532531). Its inclusion in prominent indices like S&P BSE Healthcare, BSE 1000, Nifty Microcap 250 Index, Nifty Total Market, S&P BSE MidSmallCap, S&P BSE SmallCap, and S&P BSE AllCap underscores the company’s relevance in India’s pharmaceutical and healthcare sector.

Strides Pharma stock price is closely tracked by retail and institutional investors. Its inclusion in major indices reflects its market capitalisation, regulatory compliance, and scale in the formulations, APIs, and biosimilars business. Listing on NSE and BSE ensures liquidity, while index presence drives institutional holdings and benchmark tracking in the pharmaceutical sector.

Strides Pharma Stock Performance and Strides Pharma Share Price History

Strides Pharma share price on NSE and BSE reflects its status as a key player in the global generic pharmaceuticals market. Performance is driven by product filings, USFDA approvals, manufacturing compliance, and expansion in regulated markets. Investors compare Strides Pharma share price today with the Nifty Pharma index and peer pharmaceutical companies to gauge relative performance.

These underlying factors are often visible through real market movements across different periods. Similar trends are observed during earnings-driven movements. Broader sector strength has also played a role in supporting Strides Pharma share price. In addition to operational and sector-led factors, corporate actions such as bonus issues, stock splits, or rights issues can also have a significant impact on Strides Pharma share price movements in the short-term, even when a company’s fundamentals remain strong.

While short-term movements reflect events and announcements, longer-term valuation trends are visible through Strides Pharma share price 52-week high and low, providing context beyond daily or weekly changes. Highs indicate strong product pipeline and regulatory approvals, while lows align with market corrections or sector volatility. These levels capture impacts of regulatory actions, currency fluctuations, growth expectations, and earnings visibility, providing context for the stock’s historical performance.

Strides Pharma’s stock performance reflects the trading behaviour of a pharmaceutical company operating within India’s highly regulated drug manufacturing landscape. The company’s diversified product portfolio, focus on regulated markets like the US and Europe, and its balanced approach between generics and branded formulations have shaped its Strides Pharma share price history. Over time, the stock has shown periods of significant growth and phases of consolidation.

The stock’s journey has been marked by high volatility, with its highest end-of-day price reaching ₹1635.91 on October 17, 2024, and its lowest at ₹52.87 on March 9, 2009. The early 2000s witnessed strong growth, particularly between 2003 and 2007, driven by aggressive expansion. The Strides Pharma stock price experienced a severe correction during the global financial crisis in 2008, with an annual decline of 68.57%, followed by a strong recovery of 157.37% in 2009 and 85.33% in 2010.

The period between 2011 and 2017 saw mixed performance. The Strides Pharma share price rose 175.32% in 2012 but faced a sharp decline of 66.82% in 2013. It rebounded strongly with a 167.60% return in 2014, only to face a series of declines from 2016 to 2018. The stock showed resilience during the COVID-19 pandemic, surging 144.03% in 2020 as demand for certain pharmaceutical products increased. More recently, the Strides Pharma share price delivered strong returns of 83.43% in 2023 and 28.41% in 2025, while experiencing a marginal decline of 0.06% in 2026 (year-to-date).

Strides Pharma’s stock performance over time has closely followed India’s economic cycles and the company’s own operational milestones. For instance, the Strides Pharma share price reached an all-time high above ₹1635 in October 2024, supported by strong investor confidence and positive business developments. Over three years, the stock has delivered a return of 235.23%, significantly outperforming the broader market, while the five-year return stands at 16.91%, and the ten-year return is -12.81%, highlighting the volatile nature of the stock.

Despite COVID-19 disruptions, Strides Pharma shares remained in focus. While the broader market faced uncertainty, the pharmaceutical sector saw increased attention. The company’s operational resilience and focus on essential medicines helped the Strides Pharma stock price navigate the pandemic’s challenges, though it was still subject to overall market volatility during the period.

When looking at recent performance, the Strides Pharma share price saw a 26.86% return over one year, with its 52-week high at ₹1025 and low at ₹513.05. The stock’s three-year high stands at ₹1675 and low at ₹273.15. This performance can be attributed to a combination of factors, including strong earnings growth, successful product launches, and a generally favourable outlook for the pharmaceutical sector. Periods of decline, such as the 49.12% drop in 2021, often correlate with market corrections, sector-wide sell-offs, or company-specific events like regulatory delays or increased competition.

Strides Pharma Investor Relevance and Role in Portfolio

Strides Pharma is considered a key holding in small-cap and mid-cap pharmaceutical portfolios, offering exposure to the generic drug market in the US, branded generics in emerging markets, and the growing biosimilars space. Its inclusion in indices like the Nifty Microcap 250 and S&P BSE SmallCap underscores its economic and strategic importance. A diversified product portfolio, focus on high-growth regulated markets, and an improving compliance track record make it a notable choice for long-term institutional allocations.

Strides Pharma equity is held by a broad mix of leading domestic and international institutional investors, reflecting its prominence in India’s pharmaceutical sector. Top institutional stakeholders include Quant Mutual Fund, Bandhan Mutual Fund, iShares, Vanguard, Axis Mutual Fund, Aditya Birla Sun Life Mutual Fund, the Government Pension Fund Global, and Mackenzie Emerging Markets Fund.

Prominent mutual fund holders include Quant Mutual Fund’s Small Cap Fund and Multi Cap Fund, Bandhan Mutual Fund’s Small Cap Fund, iShares Core MSCI Emerging Markets ETF, Vanguard Total International Stock ETF, Vanguard FTSE Emerging Markets ETF, Axis Mutual Fund’s Small Cap Fund, and Aditya Birla Sun Life Mutual Fund’s Pharma & Healthcare Fund. This broad investor base underscores the company’s role as a targeted holding in both domestic and global portfolios.

Beyond fundamentals and ownership, Strides Pharma’s stock is actively monitored in derivatives markets. Technical indicators such as Strides Pharma RSI, MACD, and MFI provide additional insight into short-term momentum shifts in Strides Pharma stock price. While primarily used for near-term trading, these tools can also help portfolio managers gauge market sentiment and potential volatility around major events like earnings announcements or regulatory decisions.

Strides Pharma’s beta has generally remained above 1.0, reflecting its nature as a mid-cap pharmaceutical stock with higher volatility compared to the broader market. Historical beta figures show that Strides Pharma’s beta is 1.43 for the long term. The daily beta for a one-month range is 0.0139, and for a three-month range is 0.398. Over a weekly period, the beta is 1.16 for one year and 1.26 for two years. For a two-week period over two years, the beta is 1.40, while for a monthly period over two years, it is 1.04. This data indicates the stock’s volatility can vary significantly depending on the time frame, with periods of high and moderate correlation with the market.

Strides Pharma Sectoral Relevance and Peer Positioning

Strides Pharma’s sector relevance stems from its scale in regulated generics, its strong foothold in the US market, its growing branded formulations business in Africa and other emerging markets, and its strategic focus on the biosimilars segment. This establishes it as a key mid-cap pharmaceutical company supporting India’s drug manufacturing and export ecosystem. Peer comparisons with companies like Sun Pharma, Dr. Reddy’s Laboratories, Cipla, Aurobindo Pharma, Lupin, and Glenmark focus on ANDA filings, USFDA compliance, revenue from regulated markets, R&D pipeline, and geographic diversification rather than short-term stock moves. These benchmarks help investors assess operational scale, efficiency, and regulatory adherence. Institutional tracking of product approvals, manufacturing compliance, and market expansion further highlights Strides Pharma’s systemic importance and positioning within India’s broader pharmaceutical market.

Strides Pharma’s sectoral importance is also reflected in financial and market metrics that demonstrate its scale, stability, and systemic impact.

Strides Pharma market cap underscores its prominence and influence within India’s pharmaceutical sector. As of March 2026, the market cap stands at ₹85.11 Billion. The company’s market cap has seen significant fluctuations over the years. In 2005, it was ₹10.80 Billion. It rose to ₹12.89 Billion in 2006 but fell to ₹9.92 Billion in 2007. A sharp decline in 2008 brought it to ₹3.57 Billion, before a strong recovery to ₹9.61 Billion in 2009. The market cap grew to ₹25.90 Billion in 2010 and peaked at ₹94.93 Billion in 2016. A period of consolidation followed, with the market cap at ₹32.41 Billion in 2019 before a major surge to ₹78.71 Billion in 2020. After some correction, it has grown to its current level from ₹59.71 Billion in 2023 and ₹62.90 Billion in 2024, showing a 33.4% increase in 2025 and a further 1.43% change in 2026.

Strides Pharma earnings highlight its operational performance and income generation from its diverse business segments. In 2025 (TTM), earnings stand at ₹7.39 Billion. The earnings trajectory has been volatile. In 2015, the company reported a loss of -₹5.4 Billion. This turned to a profit of ₹4.82 Billion in 2016. Earnings fell to ₹3.86 Billion in 2017 and further to ₹1.05 Billion in 2018. A strong rebound in 2019 saw earnings reach ₹4.69 Billion, followed by a decline to ₹1.25 Billion in 2020. The company reported losses again in 2021 and 2022, at -₹3.43 Billion and -₹1.83 Billion respectively. A turnaround occurred in 2023 with earnings of ₹1.07 Billion, followed by a 502.72% increase in 2024 to ₹6.47 Billion. The current TTM earnings of ₹7.39 Billion represent a 14.3% increase over 2024 levels.

Strides Pharma EPS provides insight into the company’s profitability on a per-share basis. As of 2025 (TTM), the EPS is ₹50.11. Looking at historical annual EPS, the figure was ₹51.62 in 2016. It declined to ₹33.70 in 2017, a decrease of 34.72%. A significant increase was seen in 2018 when EPS rose by 294.92% to ₹133.08. Following this peak, the company faced challenges, with EPS turning negative in subsequent years before returning to positive territory more recently. The most recent data indicates a substantial recovery in per-share earnings, aligning with the company’s improved financial performance and strategic focus on high-value products and markets.

Strides Pharma P/E ratio demonstrates how the market values the company’s earnings relative to its revenue streams, regulatory environment, and growth prospects. As of March 2026 (TTM), the P/E ratio is 2.09. Historically, the P/E ratio was 25.3 at the end of 2016. It rose to 31.1 at the end of 2017, an increase of 23.21%. The P/E ratio then saw a dramatic correction, falling by 85.18% to 4.61 at the end of 2018. This sharp decline reflects a period where the company’s earnings changed significantly relative to its stock price. The current low P/E ratio of 2.09 suggests a valuation where the market has priced in recent earnings growth.

Summary

Strides Pharma Science Limited is a global pharmaceutical company with a strong presence in regulated markets. Its market presence on the NSE and BSE, along with its inclusion in various indices, reflects its role in the pharmaceutical sector. The Strides Pharma share price has experienced significant volatility over the years, driven by earnings, regulatory outcomes, and sector trends. A diverse base of institutional investors and key financial metrics offer insight into the company’s market position and operational journey over the long term.